The 13D Report
The 13D Report
Shareholder activism
⌘K
Signup free
activistletters

Daktronics (DAKT) Faces Alta Fox Push for CEO/Chair Split, Poison Pill Removal, and Path to $40+ Share Price

Summary

Alta Fox (12% holder) is pushing for major governance and leadership changes at Daktronics, citing severe underperformance under CEO/Chair Reece Kurtenbach, nepotism, weak financial controls, and shareholder-unfriendly policies. It calls for board refreshment, splitting the CEO/Chair roles, removing the poison pill, replacing the CFO, and improving capital allocation and investor communication. Alta Fox argues these changes could unlock significant value, projecting the stock could more than double by FY28 .

Company Name: DAKTRONICS INC /SD/
Symbol: DAKT
Filing Date: Dec-11-2024
Filer Name: ALTA FOX OPPORTUNITIES FUND, LP

Download Presentation
Alta Fox-Dec-11-2024.pdf
8 MB
download-circle

Source:

https://www.sec.gov/Archives/edgar/data/915779/000153949724002619/exh99-1.htm

Member discussion

More like this

STAAR Surgical (STAA): Broadwood Partners Urges Shareholders to Reject Alcon Merger Over Governance and Valuation Concerns

Summary Broadwood Partners’ presentation argues that STAAR Surgical’s sale to Alcon is ill-timed, flawed, and undervalued. It claims STAAR’

Khrom Capital Pushes Acadia Healthcare (ACHC) Board to Pursue Sale, Slams Entrenched Leadership and Poor Capital Allocation

Summary Khrom Capital, owning 5.5% of Acadia Healthcare, criticized the company’s decade-long underperformance, poor capital allocation, and entrenched

STAAR Surgical (STAA): Broadwood Capital Urges Shareholders to Reject Alcon Merger, Highlighting Governance Conflicts and Poor Timing

Summary Broadwood Capital, owning 27.5% of STAAR Surgical, urged shareholders to vote against the proposed $28-per-share sale to Alcon,

Al Hartman Presses Silver Star Properties REIT (SLVS) Holders: Reject Current Board, Back Liquidation Plan Amid Alleged Misconduct and Value Destruction

Summary Al Hartman’s Hartman Shareholder Alliance urges Silver Star investors to vote the BLUE proxy as a “last chance”

Broadwood Partners Challenges STAAR Surgical (STAA) Sale to Alcon, Citing Inopportune Timing, Governance Issues, and Undervaluation

Summary Broadwood Partners, STAAR Surgical’s largest shareholder with a 27.5% stake, urged stockholders to vote against the proposed

Yunqi Capital Challenges STAAR Surgical (STAA)–Alcon Deal, Citing Undervaluation, Weak China Outlook Assumptions, and Governance Failures

Summary Yunqi Capital, a 5.1% shareholder of STAAR Surgical, announced it will vote against the company’s proposed $28